133 related articles for article (PubMed ID: 11353448)
1. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.
Mihara K; Suzuki A; Kondo T; Yasui-Furukori N; Ono S; Otani K; Kaneko S; Inoue Y
Am J Med Genet; 2001 Apr; 105(3):271-4. PubMed ID: 11353448
[TBL] [Abstract][Full Text] [Related]
2. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene.
Mihara K; Kondo T; Suzuki A; Yasui N; Nagashima U; Ono S; Otani K; Kaneko S
Psychopharmacology (Berl); 2000 Apr; 149(3):246-50. PubMed ID: 10823405
[TBL] [Abstract][Full Text] [Related]
3. No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study.
Mihara K; Suzuki A; Kondo T; Nagashima U; Ono S; Otani K; Kaneko S
Am J Med Genet; 2000 Jun; 96(3):422-4. PubMed ID: 10898926
[TBL] [Abstract][Full Text] [Related]
4. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.
Suzuki A; Mihara K; Kondo T; Tanaka O; Nagashima U; Otani K; Kaneko S
Pharmacogenetics; 2000 Jun; 10(4):335-41. PubMed ID: 10862524
[TBL] [Abstract][Full Text] [Related]
5. Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.
Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Otani K; Furukori H; Kaneko S; Inoue Y
Eur Arch Psychiatry Clin Neurosci; 2001; 251(2):57-9. PubMed ID: 11407439
[TBL] [Abstract][Full Text] [Related]
6. No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study.
Mihara K; Kondo T; Suzuki A; Yasui N; Ono S; Otani K; Kaneko S
Psychiatry Res; 2001 Feb; 101(1):33-8. PubMed ID: 11223117
[TBL] [Abstract][Full Text] [Related]
7. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Ishida M; Furukori H; Kaneko S; Inoue Y; Otani K
Pharmacogenetics; 2001 Aug; 11(6):545-50. PubMed ID: 11505224
[TBL] [Abstract][Full Text] [Related]
8. Association between Taq1 a dopamine D2 receptor polymorphism and psychopathology of schizophrenia in Japanese patients.
Suzuki A; Kondo T; Mihara K; Furukori H; Nagashima U; Ono S; Otani K; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2000 Oct; 24(7):1105-13. PubMed ID: 11131175
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
[TBL] [Abstract][Full Text] [Related]
10. Prolactin response to bromperidol treatment in schizophrenic patients.
Yasui N; Kondo T; Otani K; Ishida M; Mihara K; Suzuki A; Kaneko S; Inoue Y
Pharmacol Toxicol; 1998 Mar; 82(3):153-6. PubMed ID: 9553995
[TBL] [Abstract][Full Text] [Related]
11. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
Calarge CA; Ellingrod VL; Acion L; Miller DD; Moline J; Tansey MJ; Schlechte JA
Pharmacogenet Genomics; 2009 May; 19(5):373-82. PubMed ID: 19339912
[TBL] [Abstract][Full Text] [Related]
12. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.
Young RM; Lawford BR; Barnes M; Burton SC; Ritchie T; Ward WK; Noble EP
Br J Psychiatry; 2004 Aug; 185():147-51. PubMed ID: 15286066
[TBL] [Abstract][Full Text] [Related]
13. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.
Thompson J; Thomas N; Singleton A; Piggott M; Lloyd S; Perry EK; Morris CM; Perry RH; Ferrier IN; Court JA
Pharmacogenetics; 1997 Dec; 7(6):479-84. PubMed ID: 9429233
[TBL] [Abstract][Full Text] [Related]
14. Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients.
Kondo T; Mihara K; Suzuki A; Yasui-Furukori N; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):921-6. PubMed ID: 14499308
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.
Yasui-Furukori N; Kondo T; Suzuki A; Mihara K; Kaneko S; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):575-8. PubMed ID: 11999910
[TBL] [Abstract][Full Text] [Related]
16. Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis.
Miura I; Zhang JP; Hagi K; Lencz T; Kane JM; Yabe H; Malhotra AK; Correll CU
Psychoneuroendocrinology; 2016 Oct; 72():1-10. PubMed ID: 27333159
[TBL] [Abstract][Full Text] [Related]
17. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
[TBL] [Abstract][Full Text] [Related]
18. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
[TBL] [Abstract][Full Text] [Related]
19. Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.
Charan A; Shewade DG; Rajkumar RP; Chandrasekaran A
Psychiatry Res; 2016 Jun; 240():209-213. PubMed ID: 27111215
[TBL] [Abstract][Full Text] [Related]
20. D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene.
Laruelle M; Gelernter J; Innis RB
Mol Psychiatry; 1998 May; 3(3):261-5. PubMed ID: 9672902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
